1.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

2.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

3.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

4.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

5.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

6.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

7.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

8.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

9.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

1.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

2.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

3.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

4.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

5.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

6.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

7.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

8.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

9.

Alcohol consumption changes during the first COVID-19 lockdown: an online population survey in a convenience sample of French-speaking Belgian residents.

1.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

2.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

3.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

4.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

5.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

6.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

7.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

8.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

9.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

1.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

2.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

3.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

4.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

5.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

6.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

7.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

8.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

9.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

1.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

2.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

3.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

4.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

5.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

6.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

7.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

8.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

9.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

1.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

2.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

3.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

4.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

5.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

6.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

7.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

8.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

9.

Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital

1.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

2.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

3.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

4.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

5.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

6.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

7.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

8.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

9.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

1.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

2.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

3.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

4.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

5.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

6.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

7.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

8.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

9.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

1.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

2.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

3.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

4.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

5.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

6.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

7.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

8.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

9.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

1.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

2.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

3.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

4.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

5.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

6.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

7.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

8.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

9.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.